Search

Your search keyword '"Nussenzveig, Roberto"' showing total 375 results

Search Constraints

Start Over You searched for: Author "Nussenzveig, Roberto" Remove constraint Author: "Nussenzveig, Roberto"
375 results on '"Nussenzveig, Roberto"'

Search Results

1. Development and Validation of a Deep Learning-Based Microsatellite Instability Predictor from Prostate Cancer Whole-Slide Images

3. Differential Tumor Gene Expression Profiling of Patients With Prostate Adenocarcinoma on the Basis of BMI

4. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.

8. Differential Tumor Gene Expression Profiling of Obese and Non-Obese Patients (pts) with Prostatic Adenocarcinoma (PC)

9. Tumor transcriptomic profiling of patients (pts) with Metastatic Castration Sensitive Prostate Cancer (mCSPC) who do not achieve optimal PSA response to intensified androgen deprivation therapy (ADT-I)

10. Correlation of tumor gene expression profile and gleason score (GS) in patients (pts) with metastatic prostate cancer

12. Impact of androgen receptor alterations on cell‐free DNA genomic profiling on survival outcomes in metastatic castration‐resistant prostate cancer

15. Supplementary Figure from External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer

16. Data from External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer

17. Supplementary Table from External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer

18. Supplementary Figure from SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer

19. Supplementary Data from SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer

20. Supplementary Figure 1 from Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer

21. Supplementary Table 1 from Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer

22. Supplementary Table 2 from Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer

23. Trial Protocol from Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer

24. Data from Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer

25. Characterization of the tumor transcriptomic differences by smoking history in locally advanced or metastatic urothelial carcinoma (UC).

26. Tumor transcriptomic profiling of patients (pts) with metastatic castration sensitive prostate cancer (mCSPC) who do versus who do not achieve an optimal PSA response to intensified androgen deprivation therapy (i-ADT).

27. Correlation of age and the tumor transcriptomic profile in patients (pts) with advanced prostate cancer (PCa).

28. Correlation of tumor gene expression profile and gleason score (GS) in patients (pts) with metastatic prostate cancer.

29. Association of obesity with tumor differential gene expression and gene set enrichment pathways in advanced prostate adenocarcinoma (PCa).

30. Differences in the tumor transcriptomic profile of patients (pts) with advanced prostate cancer (PCa) with and without diabetes mellitus (DM).

31. Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis–Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting

32. Detection of BRCA1, and BRCA2 Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting

33. Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma

34. Overall survival (OS) after progression on first novel hormonal therapy (NHT) in patients (pts) with metastatic castration-sensitive versus castration-resistant prostate cancer (mCSPC versus mCRPC)

35. Tumor genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation (UCS) compared to pure urothelial carcinoma (UC)

36. Survival outcomes and characterization of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) undergoing intensified androgen deprivation therapy (ADT) who do not achieve an optimal PSA response (PSA ≤0.2 ng/mL).

37. Genomic characterization of patients (pts) with de-novo high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) compared to those without dn-hv-mCSPC.

38. Transcriptomic profiling of patients (pts) with de-novo metastatic castration-sensitive prostate cancer (DN-mCSPC) versus those with mCSPC that have relapsed from prior localized therapy (PLT-mCSPC)

39. Tumor genomic landscape in smokers compared to non-smoker patients with locally advanced or metastatic urothelial carcinoma

40. Progression-free survival (PFS) and overall survival (OS) in patients (pts) with de-novo, high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) undergoing intensified androgen deprivation therapy (ADT)

41. External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer

42. Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA

43. SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer

44. Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race

45. Abstract 5142: Clinical and genomic correlates of survival outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving intensified androgen deprivation therapy (ADT) in a real-world population

46. Abstract 5995: Tumor genomic landscape in patients (pts) with and without liver metastasis in metastatic urothelial carcinoma (mUC)

48. Tumor genomic landscape in younger compared to older patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).

50. Abstract P012: Genomic and clinical correlates of overall survival (OS) in men with newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC) undergoing intensified androgen deprivation therapy (ADT)

Catalog

Books, media, physical & digital resources